Publications

5532 Results

Alpha interferon (aIFN) + 5-fluorouracil (5-FU) + cisplatin (CDDP) in advanced squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group (SWOG) phase II trial.

Authors
M Hussain;J Benedetti;R Smith;D Schuller;J Ensley
Journal / Conference
ASCO 13:279(#897)
Year
1994
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-9062

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report.

Authors
M Hussain;M Wolf;E Marshall;ED Crawford;M Eisenberger
Journal / Conference
Journal of Clinical Oncology 12(9):1868-1875
Year
1994
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8509, SWOG-8708, SWOG-8719, SWOG-8722, SWOG-8955

Phase II trial of piroxantrone in gastric carcinoma: a Southwest Oncology Group study

Authors
A Hantel;C Tangen;WL Gluck;JS Macdonald
Journal / Conference
Investigational New Drugs 12(2):159-161
Year
1994
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-8936

A clinical analysis of new indolent lymphoma entities in the revised european american lymphoma (REAL) classification.

Authors
RI Fisher;S Dahlberg;TM Grogan
Journal / Conference
ASCO 13:379(#1287)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-7204/7205, SWOG-7426/7427, SWOG-7713/14

With > 4,600 patient-years follow-up, SWOG colorectal adjuvant study suggests that BCG may act as a chemoprevention agent.

Authors
F Panettiere
Journal / Conference
ASCO 13:171(#477)
Year
1994
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-7510

Patterns of failure and second malignancies from SWOG-8269: Concurrent cisplatin (P), etoposide (E), vincristine (V), and once daily radiotherapy (RT) for the treatment of limited small-cell lung cancer (SCLC).

Authors
L Janaki;D Rector;A Turrisi;J McCracken;R Livingston;S Giri;W Gordon;J Crowley
Journal / Conference
ASCO 13:331(#1096)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8269

Long term follow-up (F/U) from SWOG 8269: Concurrent cisplatin (P), etoposide (E), vincristine (V) and daily radiotherapy (TRT) for the treatment of limited small-cell lung cancer (LSCLC): Patterns of failure and second tumors.

Authors
A Turrisi;D Rector;LM Janaki;JD McCracken;R Livingston;SP Giri;W Gordon;J Crowley
Journal / Conference
Lung Cancer 11(Suppl.1):172(#666)
Year
1994
Research Committee(s)
Lung
Study Number(s)
SWOG-8269

African americans treated on SWOG NHL studies: Similar incidence, received dose intensity and outcome to caucasian patients.

Authors
S Dahlberg;RI Fisher;CA Coltman
Journal / Conference
ASCO 13:370(#1251)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8410, SWOG-8503, SWOG-8508, SWOG-8516 (INT-0067)

Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: An analysis of SWOG-8516 (INT 0067) - the national high priority lymphoma study - a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B.

Authors
ER Gaynor;S Dahlberg;RI Fisher
Journal / Conference
ASCO 13:370(#1250)
Year
1994
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8516 (INT-0067)

Standard VAD (SWOG-8624) versus total therapy (TT) with 2 autotransplants (AT) for untreated multiple myeloma (MM).

Authors
J Crowley;S Jagannath;S Salmon;DH Vesole;G Tricot;B Barlogie
Journal / Conference
ASCO 13:410(#1401)
Year
1994
Research Committee(s)
Myeloma
Study Number(s)
SWOG-8624